Terminated PHASE4 INTERVENTIONAL 1-arm NCT04287348

Intravitreal Brolucizumab in Neovascular Age-related Macular Degeneration With Limited Response to Aflibercept (ROBIN)

Sponsor: Novartis

Conditions Neovascular Age-related Macular Degeneration

Interventions Brolucizumab 6 mg solution for intravitreal injection

Updated 7 times since 2020 Last updated: Dec 8, 2021 Started: Jul 20, 2020 Primary completion: Nov 22, 2021 Completion: Nov 22, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

due to safety letter beovu from Novartis

Other terminated trials from Novartis

See all terminations from Novartis

This PHASE4 trial investigates Neovascular Age-related Macular Degeneration and is currently terminated or withdrawn. Novartis leads this study, which shows 7 recorded versions since 2020 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE4
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE4
Jan 2022 — Jul 2024 [monthly]

Terminated PHASE4

Status: Recruiting → Terminated
Jan 2021 — Jan 2022 [monthly]

Recruiting PHASE4
Sep 2020 — Jan 2021 [monthly]

Recruiting PHASE4

Status: Not Yet Recruiting → Recruiting

▶ Show 2 earlier versions

Apr 2020 — Sep 2020 [monthly]

Not Yet Recruiting PHASE4
Mar 2020 — Apr 2020 [monthly]

Not Yet Recruiting PHASE4

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis
Vista Klinik

Data source: Vista Klinik

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Binningen, Switzerland